Post-transplant malignancy. The role of immunosuppression

Drug Safety

Volumn 23, Issue 2, 2000, Pages 101-113

  Penn, Israel ^a   Alexander, J Wesley ^a,b   Blaine, Kay ^a,c  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; AZATHIOPRINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RETINOID; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE;

ANUS CARCINOMA; CANCER RISK; CARCINOMA IN SITU; EPSTEIN BARR VIRUS; GENITAL TRACT CANCER; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY CARCINOMA; LIP CANCER; LIVER CARCINOMA; LYMPHOMA; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SUNLIGHT PROTECTION; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION;

EID: 0033853911     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200023020-00002     Document Type: Review

References (71)

1. 1. Penn I, Hammond W, Brettschneider L, et al. Malignant lymphomas in transplantation patients. Transplant Proc 1969; 1: 106-12
2. 2. Penn I. Why do immunosuppressed patients develop cancer? In: Pimentel E, editor. Critical reviews in oncogenesis. Boca Raton (FL): CRC Press, 1989: 27-52
3. 3. Penn I. The problem of cancer in organ transplant recipients: an overview. Transplant Sci 1994; 4: 23-32
4. 4. Penn I. Malignancy after immunosuppressive therapy: how can the risk be reduced? Clin Immunother 1995; 9: 207-18
5. 5. Penn I. Posttransplant malignancies. Transplant Proc 1999; 31 (1-2): 1260-2
6. 6. Penn I. De novo cancers in organ allograft recipients. Curr Opin Organ Transplant 1995; 3: 188-96
7. 7. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985; 78 Suppl. 1A: 44-9
8. 8. Sheil AGR. Skin cancer in renal transplant recipients. Transplant Sci 1994; 4: 42-5
9. 9. Blohme I, Brynger H. Malignant disease in renal transplant patients. Transplantation 1985; 39: 23-35
10. 10. Harwood AR, Osoba D, Hofstader SL, et al. Kaposi's sarcoma in recipients of renal transplants. Am J Med 1979; 67 (5): 759-65
11. 11. Schröter GPJ, Weil III R, Penn I, et al. Hepatocellular carcinoma associated with chronic hepatitis B virus infection after kidney transplantation [letter]. Lancet 1982; 2: 381-2
12. 12. Sillman F, Stanek A, Sedlis A, et al. The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women. Am J Obstet Gynecol 1984; 150: 300-8
13. 13. Porreco R, Penn I, Droegemueller W, et al. Gynecologic malignancies in immunosuppressed organ homograft recipients. Obstet Gynecol 1975; 45: 359-64
14. 14. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Skin cancers in organ transplant recipients. Ann Transplant 1997; 2: 28-32
15. 15. Sheil AGR, Disney APS, Mathew TH, et al. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993; 25: 1383-4
16. 16. Hartevelt MM, Bouwes-Bavinck JN, Koote AM, et al. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990; 49 (3): 506-9
17. 17. Mullen DL, Silberberg SG, Penn I, et al. Squamous cell carcinoma of the skin and lip in renal homograft recipients. Cancer 1976; 37: 729-34
18. 18. Barr BB, Benton EC, McLaren K, et al. Papillomavirus infection and skin cancer in renal allograft recipients. Lancet 1989; 2 (8656): 224-5
19. 19. Glover MT, Niranjan N, Kwan JTC, et al. Non-melanoma skin cancer in renal transplant recipients: the extent of the problem and a strategy for management. Br J Plast Surg 1994; 47: 86-9
20. 20. McGregor JM, Berkhout RJM, Rozycka M, et al. Mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomavirus status. Oncogene 1997; 15: 1737-40
21. 21. Festenstein H, Garrido F. MHC antigens and malignancy. Nature 1986; 322: 502-3
22. 22. Dausset J, Colombani J, Hors J. Major histocompatibility complex and cancer, with special reference to human familial tumors (Hodgkin's disease and other malignancies). Cancer Surv 1982; 1: 119-47
23. 23. Bouwes Bavinck JN. Epidemiological aspects of immunosuppression: role of exposure to sunlight and human papillomavirus on the development of skin cancer. Hum Exp Toxicol 1995; 14: 98
24. 24. Bouwes Bavinck JN, Claas FJJ, Hardie D, et al. Relation between HLA Antigens and skin cancer in renal transplant recipients in Queensland, Australia. J Invest Dermatol 1997; 1008: 708-11
25. 25. Lennard L, Thomas M, Harrington C, et al. Skin cancer in renal transplant patients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells. Br J Dermatol 1985; 113: 723-9
26. 26. Hemmens VJ, Moore DE. Photochemical sensitization by azathioprine and its metabolites: II. Azathioprine and nitroimidazole metabolites. Photochem Photobiol 1986; 43 (3): 257-62
27. 27. Bouwes Bavinck JN, Hardie D, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. Transplantation 1996; 61: 715-21
28. 28. Nalesnik MA. Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant 1997; 2: 33-40
29. 29. Nalesnik MA, Locker J, Jaffe R, et al. Experience with post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clin Transplant 1992; 6: 249-52
30. 30. Penn I. Immunosuppressive agents, immunodeficiency states and malignancy. In: Lieberman R, Mukherjee A, editors. Principles of drug development in transplantation and autoimmunity. Austin (TX): RG Landes, 1996: 93-102
31. 31. Penn I. The role of immunosuppression in lymphoma formation. Springer Semin Immunopathol 1998; 20 (3-4): 343-55
32. 32. Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation 1995; 59: 240-4
33. 33. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1984; I: 583-7
34. 34. Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Ann Rev Med 1995; 46: 381-94
35. 35. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45: 719-27
36. 36. Cao S, Cox K, Esquivel CO, et al. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation. Transplantation 1998; 66: 851-6
37. 37. Hanto DW, Birkenbach M, Frizzera G, et al. Confirmation of the heterogeneity of post-transplant Epstein-Barr virus-associated B cell proliferations by immunoglobulin gene rearrangement analyses. Transplantation 1989; 47: 458-64
38. 38. Penn I. Sarcomas in organ allograft recipients. Transplantation 1995; 6O: 1485-91
39. 39. Penn I. Kaposi's sarcoma in transplant recipients. Transplantation 1997; 64: 669-73
40. 40. al-Sulaiman MH, Mousa DH, Rassoul Z, et al. Transplant-related Kaposi sarcoma in children. Nephrol Dial Transplant 1994; 9: 443-5
41. 41. Montagnino G, Bencini PL, Tarantino A, et al. Clinical features and course of Kaposi's sarcoma in kidney transplant patients: report of 13 cases. Am J Nephrol 1994; 14: 121-6
42. 42. al-Sulaiman MH, Al-Khader AA. Kaposi's sarcoma in renal transplant recipients. Transplant Sci 1994; 4: 46-60
43. 43. Qunibi W, Akhtar M, Sheth K, et al. Kaposi's sarcoma: the most common tumor after renal transplantation in Saudi Arabia. Am J Med 1988; 84: 225-32
44. 44. Gunawardena KA, al-Hasani MK, Haleem A, et al. Pulmonary Kaposi's sarcoma in two recipients of renal transplants. Thorax 1988; 43: 653-6
45. 45. Moore PS, Chang Y. Detection of herpes virus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 1995; 332: 1181-5
46. 46. Kedda MA, Margolius L, Kew MC, et al. Kaposi's sarcoma-associated herpesvirus in Kaposi's sarcoma occurring in immunosuppressed renal transplant recipients. Clin Transplant 1996; 10: 429-31
47. 47. Ensoli B, Barillari G, Gallo RC. Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma. Immunol Rev 1992; 127: 147-55
48. 48. Penn I. Primary kidney tumors before and after renal transplantation. Transplantation 1995; 59: 480-5
49. 49. Penn I. Cancers of the anogenital region in renal transplant recipients: analysis of 65 cases. Cancer 1986; 58: 611-6
50. 50. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries 1964-1986. Int J Cancer 1995; 60: 183-9
51. 51. Wiesner RH. A long term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998; 66: 493-9
52. 52. Jonas S, Rayes N, Neumann U, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80: 1141-50
53. 53. Penn I. Cancers in cyclosporine-treated versus azathioprine-treated patients. Transplant Proc 1996; 28: 876-8
54. 54. Penn I. Posttransplant malignancies: clinical preventative measures. In: Schmahl D, Penn I, editors. Cancers in organ transplant recipients. Berlin: Springer-Verlag, 1991: 157-60
55. 55. Pham H, Lemoine A, Salvucci M, et al. Occurrence of gammopathies and lymphoproliferative disorders in liver transplant recipients randomized to tacrolimus (FK506)-or cyclosporine-based immunosuppression. Liver Transplant Surg 1998; 4: 146-51
56. 56. Badley AD, Portela DF, Patel R, et al. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced post-transplant lymphoproliferative disorder. Liver Transplant Surg 1996; 2: 375-82
57. 57. Rowe DT, Qu L, Reyes J, et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997; 35: 1612-5
58. 58. Green M, Reyes J, Rowe D. New strategies in the prevention and management of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Curr Opin Transplant 1998; 3: 143-7
59. 59. McDiarmid SV, Jordon S, Kim GS, et al. Prevention and Preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66 (12): 1604-11
60. 60. Kuo PC, Dafoe DC, Alfrey EJ, et al. Posttransplant lymphoproliferative disorder and Epstein-Barr virus prophylaxis. Transplantation 1995; 59: 135-8
61. 61. Aris RM, Maia DM, Neuringer IP, et al. Posttransplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient. Am J Respir Crit Care Med 1996; 154: 1712-7
62. 62. Bouwes Bavinck JN, Tieben LM, van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 1933-8
63. 63. Fabia R, Levy MF, Testa G, et al. Colon carcinoma in patients undergoing liver transplantation. Am J Surg 1998; 176: 265-9
64. 64. Hickey DP, Nalesnik MA, Vivas CA, et al. Renal retransplantation in patients who lost their allografts during management of previous posttransplant lymphoproliferative disease. Clin Transplant 1990 4: 187-90
65. 65. Min AD. Does interferon precipitate rejection of liver allografts [editorial]? Hepatology 1995; 22: 1333-5
66. 66. Swinnen LJ. Diagnosis and treatment of organ transplant-related lymphoma. Curr Opin Transplant 1998; 3: 90-5
67. 67. Benkerrou M, Durandy A, Fischer A, et al. Therapy for transplant-related lymphoproliferative disease. Hematol Oncol Clin North Am 1993; 7: 467-75
68. 68. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 1997; 157: 217-22
69. 69. Emanuel DJ, Lucas KG, Mallory Jr GB, et al. Treatment of Posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation 1997; 63: 1691-4
70. 70. Nalesnik MA, Rao AS, Furukawa H, et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1997; 63: 1200-5
71. 71. Senderowicz AM, Vitetta E, Headlee D, et al. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann Intern Med 1997; 126: 882-5